Thanks for the 'heads up'. There are many things about ARTH for sharehoilders to be concerned about. The developemnt of a luiqid bandage for diabetic foot ulcers isn't one of them in my view. Treatment of diabetic foot ulcers is a major clinical problem; treatment with a wound dressing & hoping for a permanent solution is not a promising stratgey. This development is unlikely to become a competitive product in ARTH's world. ARTH shareholders should hope thatmanagement will not pursue this avenue.
The cause of diabetic foot ulcers is the underlying pathology (destruction of arterial blood supply and nerve damage) caused diabetes. Even when the wound can "heal" and be covered by skin tissue, it is likely to reappear unless the underlying pathology can be addressed (e.g., surgery). Trying to prevent this damage or to heal the wounds prior to futher necrosis (and sometimes amputation) with a topical dressing, even one with growth factors or other drugs, has been genberally unsuccessful to date.
News 
Market Data 
Discover 
